This agreement will enable Goodbody Clinic patients across the UK to access OBD’s EpiSwitch prostate screening blood test.
Launched in the UK and US in September 2023, OBD’s treatment is a blood test that significantly enhances the predictive accuracy of a standard PSA test from 55% to 94% for detecting prostate cancer.
The test is the result of nearly ten years of collaborative research involving OBD, Imperial College London, the University of East Anglia, Imperial College NHS Trust, and leading UK prostate cancer experts, as part of the PROSTAGRAM screening pilot.
George Thomas, CEO of Goodbody Clinic, said: “The rapid EpiSwitch PSE test can significantly enhance the accuracy of detecting prostate cancer, allowing us to provide better care and peace of mind to men throughout the whole country.
“We are always looking to advance our commitment to accessible, high-quality healthcare by combining the latest innovations like the PSE with access to Goodbody’s convenient clinics and home testing solutions.”
The Goodbody Clinic will now offer the test at its 140 locations across the UK, supported by its network of GPs.
Through the Goodbody Clinic website, men can order a PSE test from one of the clinic’s registered GPs, pay for the test, and schedule an appointment for their blood sample to be taken.
Patients will also have the option of booking a mobile nurse visit.
Thomas Guiel, chief operating officer of Oxford BioDynamics, added: “This agreement presents an important new point of patient access for the EpiSwitch PSE test, allowing us to further extend the availability and reach of our highly accurate prostate cancer test.”
